NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

被引：62

作者：

Schnaiter, Andrea ^{[1
]}

Paschka, Peter ^{[1
]}

Rossi, Marianna ^{[2
]}

Zenz, Thorsten ^{[1
,3
,4
]}

Buehler, Andreas ^{[1
]}

Winkler, Dirk ^{[1
]}

Cazzola, Mario ^{[2
]}

Doehner, Konstanze ^{[1
]}

Edelmann, Jennifer ^{[1
]}

Mertens, Daniel ^{[1
]}

Kless, Sabrina ^{[1
]}

Mack, Silja ^{[1
]}

Busch, Raymonde ^{[5
]}

Hallek, Michael ^{[6
]}

Doehner, Hartmut ^{[1
]}

Stilgenbauer, Stephan ^{[1
]}

机构：

[1] Univ Ulm, Dept Internal Med 3, D-89081 Ulm, Germany

[2] Fdn Ist Ricovero & Cura Carattere Sci Policlin S, Dept Internal Med & Med Oncol, Pavia, Italy

[3] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany

[4] German Canc Res Ctr, Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany

[5] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany

[6] Univ Cologne, Dept Internal Med 1, D-50931 Cologne, Germany

来源：

BLOOD | 2013年 / 122卷 / 07期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; GENOMIC ABERRATIONS; FOLLOW-UP; SURVIVAL; PROGRESSION; PROGNOSIS; DISEASE; RISK;

D O I：

10.1182/blood-2013-03-488197

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial. We found NOTCH1(mut), SF3B1(mut), and TP53(mut) in 13.4%, 17.5%, and 37.4% of patients, respectively. NOTCH1(mut) and SF3B1(mut) weremutually exclusive, whereas TP53(mut) were evenly distributed within both subgroups. Apart from correlation of SF3B1(mut) with 11q deletion (P 5.029), there were no other significant associations of the mutations with any baseline characteristics or response rates. However, NOTCH1(mut) cases had a significantly longer progression-free survival (PFS) compared with wild-type cases (15.47 vs 6.74 months; P = .025), although there was no significant difference with overall survival (OS). SF3B1(mut) had no significant impact on PFS and OS. In multivariable analyses, NOTCH1(mut) was identified as an independent favorable marker for PFS. This clinical trial is registered at www.clinicaltrials.gov as #NCT00274976.

引用

页码：1266 / 1270

页数：5

共 50 条

[21] On the way towards a ‘CLL prognostic index’: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort
D Cortese
L-A Sutton
N Cahill
K E Smedby
C Geisler
R Gunnarsson
G Juliusson
L Mansouri
R Rosenquist
Leukemia, 2014, 28 : 710 - 713
[22] On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort
Cortese, D.
Sutton, L-A
Cahill, N.
Smedby, K. E.
Geisler, C.
Gunnarsson, R.
Juliusson, G.
Mansouri, L.
Rosenquist, R.
LEUKEMIA, 2014, 28 (03) : 710 - 713
[23] Relative Impact of NOTCH1/SF3B1 Mutations, Complex Karyotype and TP53 Disruption in the Prognosis of Chronic Lymphocytic Leukemia Patients.
Ysebaert, Loic
Struski, Stephanie
Prade, Nais
Guieze, Romain
Laurent, Guy
Delabesse, Eric
BLOOD, 2012, 120 (21)
[24] Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia
Nadeu, Ferran
Delgado, Julio
Royo, Cristina
Baumann, Tycho
Stankovic, Tatjana
Pinyol, Magda
Jares, Pedro
Navarro, Alba
Martin-Garcia, David
Bea, Silvia
Salaverria, Itziar
Oldreive, Ceri
Aymerich, Marta
Suarez-Cisneros, Helena
Rozman, Maria
Villamor, Neus
Colomer, Dolors
Lopez-Guillermo, Armando
Gonzalez, Marcos
Alcoceba, Miguel
Jose Terol, Maria
Colado, Enrique
Puente, Xose S.
Lopez-Otin, Carlos
Enjuanes, Anna
Campo, Elias
BLOOD, 2016, 127 (17) : 2122 - 2130
[25] THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT
Bilous, N.
Abramenko, I.
Chumak, A.
Dyagil, I.
Martina, Z.
HAEMATOLOGICA, 2017, 102 : 711 - 711
[26] Acquisition of TP53 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients During the Course of Disease Is Associated with an Unmutated IGHV Status and Mutations in XPO1 and SF3B1
Grossmann, Vera
Kohlmann, Alexander
Schnittger, Susanne
Weissmann, Sandra
Dicker, Frank
Jeromin, Sabine
Boeck, Lucia
Alpermann, Tamara
Kern, Wolfgang
Haferlach, Torsten
Haferlach, Claudia
BLOOD, 2012, 120 (21)
[27] Modulation of the Clonal Composition in Relapsed CLL: A Study Based on Targeted Deep-Sequencing of ATM, BIRC3, NOTCH1, POT1, SF3B1, SAMHD1 and TP53
Jeromin, Sabine
Kern, Wolfgang
Schabath, Richard
Alpermann, Tamara
Nadarajah, Niroshan
Meggendorfer, Manja
Schnittger, Susanne
Haferlach, Torsten
Haferlach, Claudia
BLOOD, 2015, 126 (23)
[28] Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stilgenbauer, Stephan
Zenz, Thorsten
Winkler, Dirk
Buehler, Andreas
Schlenk, Richard F.
Groner, Silja
Busch, Raymonde
Hensel, Manfred
Duehrsen, Ulrich
Finke, Juergen
Dreger, Peter
Jaeger, Ulrich
Lengfelder, Eva
Hohloch, Karin
Soeling, Ulrike
Schlag, Rudolf
Kneba, Michael
Hallek, Michael
Doehner, Hartmut
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) : 3994 - 4001
[29] Impact of TP53 Mutations on Outcome: Results from the CLL8 Trial (FC vs. R-FC) of the GCLLSG
Zenz, T.
Hoth, P.
Busch, R.
Helfrich, H.
Winkler, D.
Buehler, A.
Patten, N.
Truong, S.
Wu, L.
Fingerle-Rowson, G.
Fischer, K.
Fink, A-M
Jaeger, U.
Boettcher, S.
Kneba, M.
Wenger, M.
Mendila, M.
Hallek, M.
Doehner, H.
Stilgenbauer, S.
ONKOLOGIE, 2010, 33 : 20 - 20
[30] IMPACT OF TP53 MUTATIONS ON OUTCOME: RESULTS FROM THE CLL8 TRIAL (FC VS. R-FC) OF THE GCLLSG
Zenz, T.
Hoth, P.
Busch, R.
Helfrich, H.
Winkler, D.
Buhler, A.
Patten, N.
Truong, N.
Wu, L.
Fingerle-Rowson, G.
Fischer, K.
Fink, A.
Jager, U.
Bottcher, S.
Kneba, M.
Wenger, M.
Mendila, M.
Hallek, M.
Dohner, H.
Stilgenbauer, S.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 223 - 223

← 1 2 3 4 5 →